WallStreetZenWallStreetZen

NASDAQ: LUNG
Pulmonx Corp Stock Forecast, Predictions & Price Target

Analyst price target for LUNG

Based on 3 analysts offering 12 month price targets for Pulmonx Corp.
Min Forecast
$10.00+36.8%
Avg Forecast
$12.67+73.28%
Max Forecast
$16.00+118.88%

Should I buy or sell LUNG stock?

Based on 3 analysts offering ratings for Pulmonx Corp.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
0 analysts 0%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LUNG stock forecasts and price targets.

LUNG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-01
lockedlocked$00.00+00.00%2024-08-01
lockedlocked$00.00+00.00%2024-06-04

1 of 1

Forecast return on equity

Is LUNG forecast to generate an efficient return?
Company
-62.3%
Industry
25.35%
Market
49.3%
LUNG's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LUNG forecast to generate an efficient return on assets?
Company
-36.52%
Industry
13.51%
LUNG is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LUNG earnings per share forecast

What is LUNG's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.64
Avg 2 year Forecast
-$1.64
Avg 3 year Forecast
-$1.46

LUNG revenue forecast

What is LUNG's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$83.3M+8.8%
Avg 2 year Forecast
$101.2M+32.19%
Avg 3 year Forecast
$121.7M+58.9%
LUNG's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LUNG revenue growth forecast

How is LUNG forecast to perform vs Medical Devices companies and vs the US market?
Company
16.56%
Industry
7.23%
Market
9.61%
LUNG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LUNG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LUNG vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
LUNG$7.31$12.67+73.28%Strong Buy
RCEL$10.79$15.00+39.02%Buy
SGHT$6.00$7.25+20.83%Buy
CLPT$11.12$15.00+34.89%Strong Buy
CERS$1.68$4.00+138.10%Strong Buy

Pulmonx Stock Forecast FAQ

Is Pulmonx Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: LUNG) stock is to Strong Buy LUNG stock.

Out of 3 analysts, 2 (66.67%) are recommending LUNG as a Strong Buy, 0 (0%) are recommending LUNG as a Buy, 1 (33.33%) are recommending LUNG as a Hold, 0 (0%) are recommending LUNG as a Sell, and 0 (0%) are recommending LUNG as a Strong Sell.

If you're new to stock investing, here's how to buy Pulmonx stock.

What is LUNG's earnings growth forecast for 2024-2026?

(NASDAQ: LUNG) Pulmonx's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 27.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.13%.

Pulmonx's earnings in 2024 is -$57,863,000.On average, 2 Wall Street analysts forecast LUNG's earnings for 2024 to be -$64,210,187, with the lowest LUNG earnings forecast at -$64,601,712, and the highest LUNG earnings forecast at -$63,818,661. On average, 2 Wall Street analysts forecast LUNG's earnings for 2025 to be -$64,014,424, with the lowest LUNG earnings forecast at -$67,342,391, and the highest LUNG earnings forecast at -$60,686,457.

In 2026, LUNG is forecast to generate -$56,966,965 in earnings, with the lowest earnings forecast at -$64,993,238 and the highest earnings forecast at -$48,940,691.

What is LUNG's revenue growth forecast for 2024-2026?

(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 16.56% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.61%.

Pulmonx's revenue in 2024 is $76,583,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2024 to be $3,262,386,479, with the lowest LUNG revenue forecast at $3,257,492,410, and the highest LUNG revenue forecast at $3,267,280,548. On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,963,608,703, with the lowest LUNG revenue forecast at $3,921,911,234, and the highest LUNG revenue forecast at $4,005,306,172.

In 2026, LUNG is forecast to generate $4,764,356,717 in revenue, with the lowest revenue forecast at $4,638,559,564 and the highest revenue forecast at $4,890,153,870.

What is LUNG's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: LUNG) forecast ROA is -36.52%, which is lower than the forecast US Medical Devices industry average of 13.51%.

What is LUNG's Price Target?

According to 3 Wall Street analysts that have issued a 1 year LUNG price target, the average LUNG price target is $12.67, with the highest LUNG stock price forecast at $16.00 and the lowest LUNG stock price forecast at $10.00.

On average, Wall Street analysts predict that Pulmonx's share price could reach $12.67 by Aug 1, 2025. The average Pulmonx stock price prediction forecasts a potential upside of 73.28% from the current LUNG share price of $7.31.

What is LUNG's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: LUNG) Pulmonx's current Earnings Per Share (EPS) is -$1.50. On average, analysts forecast that LUNG's EPS will be -$1.64 for 2024, with the lowest EPS forecast at -$1.65, and the highest EPS forecast at -$1.63. On average, analysts forecast that LUNG's EPS will be -$1.64 for 2025, with the lowest EPS forecast at -$1.72, and the highest EPS forecast at -$1.55. In 2026, LUNG's EPS is forecast to hit -$1.46 (min: -$1.66, max: -$1.25).

What is LUNG's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: LUNG) forecast ROE is -62.3%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.